Ceftibuten


Concise Prescribing Info
Indications/Uses
Resp tract infections.
Dosage/Direction for Use
Adult : PO 400 mg once daily for 10 days.
Dosage Details
Oral
Respiratory tract infections
Adult: 400 mg once daily for 10 days.
Child: >6 mth ≤45 kg: 9 mg/kg once daily for 10 days.
Renal Impairment
Patient on haemodialysis: 400 mg after each session 2 or 3 times wkly.
CrCl (mL/min) Dosage
5-29 100 mg once daily.
30-49 200 mg once daily.
Administration
Cap: May be taken with or without food.
Susp: Should be taken on an empty stomach. Take 2 hr before or 1 hr after meals.
Reconstitution
Reconstitute powd for susp at the time of dispensing by adding the amount of water specified on the container to provide a susp containing 90 mg per 5 mL. Water should be added in 2 equal parts and shake the bottle after each addition.
Contraindications
Hypersensitivity to ceftibuten and other cephalosporins.
Special Precautions
Patient w/ history of penicillin allergy, history of colitis and other GI diseases. Renal impairment. Pregnancy and lactation.
Adverse Reactions
Nausea, diarrhoea, melaena, dyspepsia, vomiting, abdominal pain; headache, dizziness; increased eosinophils, platelets, ALT, bilirubin or BUN, decreased Hb; Stevens-Johnson syndrome.
Potentially Fatal: Pseudomembranous colitis.
MonitoringParameters
Periodically monitor renal, hepatic and haematologic function w/ prolonged therapy. Observe for signs and symptoms of anaphylaxis during 1st dose.
Overdosage
Symptoms: Cerebral irritation leading to convulsions. Management: Haemodialysis may be useful in the removal from the circulation.
Drug Interactions
Enhanced nephrotoxicity of aminoglycosides. Increased serum concentration w/ probenecid. Decreased serum concentration w/ zinc salts.
Food Interaction
Food decreases rate and extent of absorption.
Lab Interference
Positive Coombs' test; false-positive serum or urine creatinine w/ Jaffe reaction; false-positive urine glucose results may occur when using Clinitest®, Benedict's or Fehling's soln.
Action
Description: Ceftibuten binds to 1 or more of the penicillin-binding proteins (PBPs) which inhibit the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Pharmacokinetics:
Absorption: Rapidly absorbed from the GI tract. Rate and extent of absorption are decreased by food. Time to peak plasma concentration: Approx 2 hr.
Distribution: Distributed into middle-ear fluid and bronchial secretions. Volume of distribution: 0.21 L/kg. Plasma protein binding: 65-77%.
Excretion: Mainly via urine (approx 56%) and faeces (39%). Plasma half-life: Approx 2-2.3 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 2-25°C. Reconstituted susp: Store between 2-8°C.
MIMS Class
ATC Classification
J01DD14 - ceftibuten ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by MIMS based on Ceftibuten from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Cedax
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in